Clinical Practice Guidelines - Resource Library-Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline

Video Transcription

Video Summary

The video content is a presentation of the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults. The presenter, Alia Khan, introduces the guideline and its development process, which followed evidence-based and GRADE methodology. Notable faculty contributors are acknowledged, with Ghada El-Hajj Fuleihan serving as the chair. The panelists disclose no conflicts of interest regarding the guideline. The presentation invites audience participation through scanning a QR code and outlines the agenda.<br /><br />Two cases are presented. The first involves a 39-year-old female with hypercalcemia of malignancy, with treatment options discussed, including hydration, calcitonin, denosumab, and zoledronic acid. The evidence and recommendations for these treatments are provided.<br /><br />The second case involves a 77-year-old woman with hypercalcemia of malignancy caused by multiple myeloma. Treatment options, specifically denosumab for refractory cases, are discussed with corresponding evidence and recommendations.<br /><br />Overall, the video summarizes the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults, highlighting treatment options, evidence, and recommendations for various scenarios.<br /><br />In terms of specific panel discussions, concerns were raised about the use of denosumab in patients with elevated creatinine and/or GFR due to increased risk of hypo and hypercalcemia, as warned by the FDA. Other topics addressed include the use of ionized calcium in multiple myeloma, the definition of refractory hypercalcemia, transitioning to different treatments, vitamin D supplementation, and managing hypocalcemia after denosumab treatment.<br /><br />The panel also discussed the treatment of hypercalcemia in parathyroid carcinoma, recommending the use of calcimimetics, intravenous bisphosphonates, or denosumab. Surgery is recognized as the ideal approach, but feasibility varies. The limitations of the evidence and the need for further research were acknowledged.

Keywords

Endocrine Society

Clinical Practice Guideline

Hypercalcemia of Malignancy

Adults

Alia Khan

Guideline Development

Evidence-based

GRADE Methodology

Treatment Options

Denosumab

Zoledronic Acid

Refractory Hypercalcemia

Hypercalcemia in Parathyroid Carcinoma


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274